A Double-Blind, Randomized, Placebo-Controlled, Multicenter, 30-Night Polysomnographic Study of MK0928 in Elderly Patients With Primary Insomnia

NCT00094666 Phase 3 TERMINATED

The purpose of the study is to test the safety and effectiveness of an Investigational Drug on insomnia in the elderly.

Details

Lead sponsor	H. Lundbeck A/S
Phase	Phase 3
Status	TERMINATED
Enrolment	465
Start date	2004-11
Completion	2007-03

Conditions

• Primary Insomnia

Interventions

• MK0928, gaboxadol / Duration of Treatment - 6 weeks
• Comparator: placebo / Duration of Treatment - 6 weeks

Primary outcomes

• Amount of time spent awake and time to fall asleep at night after two days